Solventum Framtida tillväxt
Future kriterier kontrolleras 1/6
Solventum s intäkter förväntas minska med 0.08% per år medan dess årliga intäkter förväntas växa med 3% per år. EPS förväntas tillväxt med 0.4% per år. Avkastningen på eget kapital förväntas bli 25.3% om 3 år.
Viktig information
-0.08%
Tillväxttakt i vinsten
0.41%
Tillväxttakt för EPS
| Medical Equipment vinsttillväxt | 17.0% |
| Intäkternas tillväxttakt | 3.0% |
| Framtida avkastning på eget kapital | 25.27% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 10 Sep 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Sep 04
SOLV: HIS Separation And Execution Risks Will Likely Cap Future Upside
The analyst fair value estimate for Solventum is now $70.00. This reflects higher Street price targets that focus on Q2 earnings, which were ahead of expectations, and the planned separation of the HIS segment, while still accounting for ongoing cost, dilution, and execution risks.
Uppdatering av berättelse • Aug 21
SOLV: HIS Separation And ERP Cutover Execution Will Drive Early Repricing
Solventum's analyst fair value estimate has risen from $100 to $113, reflecting updated expectations for slightly higher revenue growth and profit margins, along with a modestly lower discount rate. Recent Street research highlights the planned HIS separation and solid Q2 execution as key supports for the higher price targets.
Uppdatering av berättelse • Aug 07
SOLV: HIS Separation Will Drive Future P/E Rerating Potential
Solventum's analyst price target has been revised upward from $82.15 to $93.15 as analysts factor in stronger Q2 results, the planned separation of the HIS segment, and updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Solventum points to a mixed but generally constructive view, with several firms revising price targets higher following Q2 results and the planned separation of the Health Information Systems, or HIS, segment.Uppdatering av berättelse • Jul 24
SOLV: Execution Hurdles And ERP Cutover Will Likely Cap Future Upside
The analyst fair value estimate for Solventum has been adjusted modestly higher to $61.24 from $60.00. This reflects recent Street price target moves such as BTIG's lift to $91 and supportive commentary from several firms on potential earnings and cost saving catalysts, balanced by others flagging execution hurdles and risk/reward limits at current levels.Seeking Alpha • Jul 10
Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority
Summary Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue growth for 2026, with SOLV EPS likely at the high end of the $6.40–$6.60 range. Restructuring and portfolio optimization offer significant upside, as SOLV’s business units lack natural synergies and could be divested. SOLV stock valuation remains attractive, with DCF and EV/revenue suggesting 20%+ upside, but patient investors are required given slow growth. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 10
SOLV: ERP Cutover Execution Will Drive This Early Spin-Off Repricing
Solventum's analyst fair value estimate has been revised from $105.00 to $100.00, as analysts weigh mixed catalysts, including execution hurdles around the upcoming ERP cutover, activist overhang, AI risk to higher margin areas, and early-stage cost savings, against varying price targets ranging from $81 to $94. Analyst Commentary Street research on Solventum reflects a split view, with some firms emphasizing execution challenges and others pointing to potential upside if the company can deliver on its cost savings plans and leverage its positions in MedSurg, Dental Solutions, and Health Info Systems.Uppdatering av berättelse • Jun 26
SOLV: Margin Recovery Pace Will Likely Restrain Future Share Performance
Analysts have trimmed the Solventum fair value estimate from $71.00 to $60.00, while updating their assumptions to reflect a slightly lower discount rate, modestly positive revenue growth, a small pullback in profit margin expectations, and a reduced future P/E. They cited both recent price target revisions and fresh coverage that highlights the stock's valuation against its healthcare peers.Uppdatering av berättelse • Jun 11
SOLV: Activist Demands And Margin Repair Will Guide Future P/E Re Rating
Solventum's analyst price target has shifted modestly, with updated assumptions on discount rate, revenue growth, profit margins and future P/E. This reflects a mix of fresh Outperform initiations around $94 and recent target trims from other firms, as analysts reassess the stock following its spin from 3M.Uppdatering av berättelse • May 28
SOLV: Activist Pressure And Margin Discipline Will Shape Future P/E Re Rating
Solventum's analyst price target has shifted lower by about $2 per share as analysts balance a slightly reduced fair value estimate and profit margin outlook with updated assumptions for revenue growth, discount rate, and future P/E multiples following recent research coverage and target changes across the Street. Analyst Commentary Bullish Takeaways Bullish analysts see Solventum as a special situation with multiple potential catalysts, pointing to the company’s mix of MedSurg, Dental Solutions, and Health Info Systems as an underpinning for long term growth potential.Analysartikel • May 13
Solventum's (NYSE:SOLV) Solid Earnings May Rest On Weak Foundations
The market for Solventum Corporation's ( NYSE:SOLV ) stock was strong after it released a healthy earnings report last...Uppdatering av berättelse • Apr 29
SOLV: 2026 Capital Allocation And Margin Discipline Will Support P/E Re Rating
The analyst price target for Solventum has been trimmed by about $1, reflecting recent cuts to Street targets and updated assumptions for slightly lower revenue, a modestly higher profit margin, and a small adjustment to future P/E expectations. Analyst Commentary Recent Street research on Solventum reflects a mix of optimism and caution, with several firms revising price targets and one new initiation with a bearish stance.Uppdatering av berättelse • Apr 15
SOLV: 2026 Capital Allocation And Margin Execution Will Support Multiple Expansion
The analyst price target for Solventum has been trimmed by about $5, as analysts factor in more conservative profit margin assumptions and slightly higher required returns, despite mixed recent rating changes on the stock. Analyst Commentary Recent Street research on Solventum reflects a mix of optimism and caution, with target changes and rating shifts clustered around the latest earnings update and subsequent model revisions.Uppdatering av berättelse • Mar 22
SOLV: 2026 Capital Allocation And Medtech Positioning Will Support Multiple Expansion
Analysts have modestly raised Solventum's implied price target to about $90.17, with recent research citing updated models after Q4 earnings, a series of upgrades, and adjusted assumptions for the discount rate and future P/E as key drivers of the change. Analyst Commentary Recent Street research around Solventum centers on refreshed models after Q4 earnings, a series of rating changes, and a wide range of price targets that cluster around the low to mid double digits.Uppdatering av berättelse • Mar 07
SOLV: 2026 Medtech Positioning And Capital Allocation Agenda Will Drive Future Upside
The analyst price target for Solventum has been adjusted from $89.25 to about $90.17, reflecting updated models after recent earnings and a series of supporting revisions from multiple firms that now view it as one of their preferred MedTech ideas heading into 2026. Analyst Commentary Recent research updates on Solventum cluster around revised models after earnings and a reset of expectations for large cap MedTech into 2026, with several firms adjusting price targets and ratings as they refine their views on valuation and execution risk.Uppdatering av berättelse • Feb 21
SOLV: 2026 Medtech Setup And Top-Idea Status Will Drive Future Upside
Solventum's analyst price targets have moved modestly higher toward $105, with analysts pointing to a more constructive medtech setup into 2026 and highlighting the stock as one of their preferred large cap ideas following recent upgrades at several firms. Analyst Commentary Recent research has focused on how Solventum fits into a broader large cap medtech group, with several firms adjusting targets and ratings as they refine expectations into 2026.Uppdatering av berättelse • Feb 06
SOLV: Top-Idea Status And Buybacks Will Support Future Upside Potential
Analysts have nudged their price target on Solventum higher, with the fair value estimate moving from about $88.55 to $89.25. This change reflects updated expectations for slightly faster revenue growth and modestly higher future P/E multiples following recent upgrades and more constructive views on large cap MedTech coverage.Uppdatering av berättelse • Jan 21
SOLV: MedTech Top-Idea Status And Buybacks Will Support Gradual Upside
Analysts have lifted their price target on Solventum from about $85.64 to roughly $88.55, citing updated expectations for revenue growth, a slightly higher future P/E and recent bullish research that highlights the company as a top MedTech idea. Analyst Commentary Recent research coverage on Solventum has leaned constructive, with several reports treating the stock as a key MedTech idea and adjusting price targets accordingly.Uppdatering av berättelse • Jan 06
SOLV: Wound Therapy Guidance And Buybacks Will Support Measured, Gradual Upside Ahead
Analysts now see Solventum’s fair value inching up from US$84.36 to US$85.64, reflecting small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Solventum announced updated consensus recommendations from an international panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings, published in the International Wound Journal.Uppdatering av berättelse • Dec 13
SOLV: Portfolio Streamlining And Buybacks Will Support Balanced, Gradual Upside Ahead
Analysts have modestly raised their price target on Solventum, reflecting an updated fair value estimate of approximately $84.36 from about $82.80, as they factor in the impact of the company's P&F business sale and slightly improved long term valuation assumptions. Analyst Commentary Bullish Takeaways Bullish analysts view the P&F business sale as a cleaner portfolio move that supports a more focused operating model and clearer earnings trajectory.Analysartikel • Dec 05
Solventum Corporation (NYSE:SOLV) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Solventum Corporation ( NYSE:SOLV ) shares have had a really impressive month, gaining 26% after a shaky period...Uppdatering av berättelse • Nov 28
SOLV: Portfolio Changes And Share Buybacks Will Support Measured Improvement Ahead
Analysts have revised Solventum's price target slightly downward to $82.80 from $84.11. This change reflects updated expectations for revenue growth and profitability following recent strategic changes and portfolio reshaping initiatives.Uppdatering av berättelse • Nov 14
SOLV: Portfolio Reshaping And Sale Will Drive Momentum Into 2025
Analysts have revised Solventum's price target upward by $3 to $82. They cite recent portfolio changes as well as expectations for an improved cost structure and organic growth.Uppdatering av berättelse • Oct 31
SOLV: Portfolio Reshaping And Cost Controls Will Improve Outlook For 2025
Solventum's analyst price target has been raised by $3 to $82, as analysts point to recent portfolio reshaping and the sale of the P&F business as key factors that support an improved outlook. Analyst Commentary Recent analyst updates reflect a mix of positive developments and continued caution surrounding Solventum’s performance and outlook.Uppdatering av berättelse • Oct 17
Commercial Restructuring And New Product Launches Will Broaden International Reach
Solventum's analyst price target increased modestly to $82 from $79, as analysts point to the recent divestiture of its P&F business, along with ongoing improvements in its portfolio and cost structure, as key drivers for the update. Analyst Commentary Analyst sentiment on Solventum reflects a balance of cautious optimism and highlighted risks as the company navigates portfolio changes and future growth prospects.Uppdatering av berättelse • Oct 03
Commercial Restructuring And New Product Launches Will Broaden International Reach
Analysts have modestly lowered their average price target for Solventum by $1.60 to $85.11, citing recent portfolio reshaping and tempered profit margin expectations. Analyst Commentary Recent analyst research reflects a mix of optimism and caution regarding Solventum's future valuation and growth trajectory.Uppdatering av berättelse • Sep 04
Commercial Restructuring And New Product Launches Will Broaden International Reach
As there were no material changes in Solventum’s revenue growth or net profit margin forecasts, the consensus analyst price target remains unchanged at $86.71. What's in the News Solventum completed the $4 billion divestiture of its Purification & Filtration business to Thermo Fisher, using most of the $3.4 billion net proceeds to reduce debt and strengthen the balance sheet while raising FY25 organic sales growth, adjusted EPS, free cash flow, and operating margin guidance.
Ny berättelse • Mar 30
New VAC Product And AI Will Simplify Procedures
Streamlining operations and divesting non-core assets are expected to improve margins, reduce leverage, and focus growth efforts on core segments.Seeking Alpha • Feb 26
Solventum: An Impressive Sale Of Purification And Filtration
Summary Solventum's impressive $4.1 billion divestment to Thermo Fisher significantly reduces debt, enhancing its financial stability and potentially boosting earnings per share. The strategic sale has made me more optimistic about Solventum's future, maintaining a modest long position. The company's valuation remains attractive, with earnings multiples reasonable, especially considering the substantial deleveraging progress. Solventum still needs to achieve solid organic growth, but the recent positive developments justify continued investment. Read the full article on Seeking AlphaSeeking Alpha • Nov 30
Solventum: Concerns After A Partial Re-Rating
Summary Solventum's sales and margins have shown modest improvement, but concerns about 2025 earnings due to non-quantified headwinds make me cautious at current levels. The company, spun off from 3M, has a diversified healthcare portfolio but has faced flattish sales and high debt, impacting its valuation. Despite recent stock gains and improved guidance, potential 2025 earnings pressure from costs and investments warrants a cautious approach, prompting me to trim my position. Solventum's exploration of selling its purification filtration business could be a potential catalyst, but the impact remains uncertain without indicative pricing. Read the full article on Seeking AlphaPrognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 8,841 | 873 | 933 | 1,343 | 11 |
| 12/31/2027 | 8,514 | 686 | 802 | 1,100 | 13 |
| 12/31/2026 | 8,228 | 319 | 272 | 674 | 13 |
| 6/30/2026 | 8,310 | 1,434 | -118 | 209 | N/A |
| 3/31/2026 | 8,262 | 1,432 | -203 | 151 | N/A |
| 12/31/2025 | 8,325 | 1,556 | -10 | 369 | N/A |
| 9/30/2025 | 8,402 | 1,524 | 50 | 493 | N/A |
| 6/30/2025 | 8,388 | 380 | 147 | 586 | N/A |
| 3/31/2025 | 8,308 | 379 | 385 | 772 | N/A |
| 12/31/2024 | 8,254 | 479 | 805 | 1,185 | N/A |
| 9/30/2024 | 8,215 | 720 | 1,172 | 1,513 | N/A |
| 6/30/2024 | 8,207 | 1,058 | 1,523 | 1,837 | N/A |
| 3/31/2024 | 8,202 | 1,290 | 1,521 | 1,848 | N/A |
| 12/31/2023 | 8,197 | 1,346 | 1,625 | 1,915 | N/A |
| 9/30/2023 | 8,166 | 1,381 | 1,530 | 1,814 | N/A |
| 6/30/2023 | 8,101 | 1,256 | 1,542 | 1,817 | N/A |
| 3/31/2023 | 8,083 | 1,286 | 1,560 | 1,820 | N/A |
| 12/31/2022 | 8,130 | 1,343 | 1,428 | 1,679 | N/A |
| 12/31/2021 | 8,171 | 1,460 | 1,925 | 2,202 | N/A |
| 12/31/2020 | 7,281 | 1,138 | 1,755 | 2,026 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: SOLV s intäkter förväntas minska under de kommande 3 åren ( -0.08% per år).
Resultat vs marknad: SOLV s intäkter förväntas minska under de kommande 3 åren ( -0.08% per år).
Höga tillväxtresultat: SOLV s intäkter förväntas minska under de kommande 3 åren.
Intäkt vs marknad: SOLV s intäkter ( 3% per år) förväntas växa långsammare än marknaden för US ( 13.4% per år).
Hög tillväxtintäkter: SOLV s intäkter ( 3% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: SOLV s avkastning på eget kapital förväntas bli hög om 3 år ( 25.3 %)
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/14 11:27 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Solventum Corporation bevakas av 19 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |